Based on a retrospective study of patients treated for HCV infection in Taiwan, a polymorphism in IFNL3 (formerly known as IL28B) was found to be an independent risk factor for development of HCC following treatment. This evidence concerns the gene IFNL3 and hepatocellular carcinoma.